Medidata Solutions Inc. (NASDAQ:MDSO) had its price target hoisted by research analysts at Jefferies Group from $41.00 to $46.00 in a note issued to investors on Tuesday. The firm presently has an “underperform” rating on the stock. Jefferies Group’s price objective would suggest a potential downside of 16.71% from the company’s previous close.

A number of other equities research analysts have also issued reports on MDSO. Deutsche Bank AG upped their target price on shares of Medidata Solutions from $56.00 to $58.00 and gave the company a “buy” rating in a research note on Tuesday, September 13th. TheStreet upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Thursday, August 25th. Morgan Stanley restated a “buy” rating and issued a $61.00 target price on shares of Medidata Solutions in a research note on Thursday, August 25th. Finally, Zacks Investment Research upgraded shares of Medidata Solutions from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Tuesday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $54.80.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Medidata Solutions (NASDAQ:MDSO) opened at 55.23 on Tuesday. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of 126.10 and a beta of 1.49. The company’s 50 day moving average price is $51.53 and its 200-day moving average price is $50.74. Medidata Solutions has a 12-month low of $30.22 and a 12-month high of $57.85.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Tuesday, October 25th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.02. Medidata Solutions had a net margin of 5.70% and a return on equity of 10.46%. The firm had revenue of $120.10 million for the quarter, compared to analyst estimates of $118.96 million. During the same quarter in the previous year, the business posted $0.25 EPS. The firm’s revenue was up 16.5% compared to the same quarter last year. On average, analysts forecast that Medidata Solutions will post $1.02 EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of international copyright & trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2016/11/22/medidata-solutions-mdso-sell-rating-reaffirmed-at-jefferies-group.html.

In other Medidata Solutions news, CEO Tarek Sherif sold 7,500 shares of the company’s stock in a transaction dated Wednesday, November 2nd. The shares were sold at an average price of $46.70, for a total value of $350,250.00. Following the completion of the transaction, the chief executive officer now owns 814,580 shares in the company, valued at approximately $38,040,886. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Eileen Schloss sold 3,831 shares of the company’s stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $56.60, for a total transaction of $216,834.60. Following the completion of the transaction, the executive vice president now owns 33,561 shares of the company’s stock, valued at approximately $1,899,552.60. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of MDSO. Acrospire Investment Management LLC boosted its position in Medidata Solutions by 90.0% in the third quarter. Acrospire Investment Management LLC now owns 1,900 shares of the company’s stock valued at $106,000 after buying an additional 900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Medidata Solutions by 13.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,978 shares of the company’s stock worth $110,000 after buying an additional 227 shares in the last quarter. LS Investment Advisors LLC raised its stake in shares of Medidata Solutions by 9.2% in the second quarter. LS Investment Advisors LLC now owns 2,411 shares of the company’s stock worth $113,000 after buying an additional 203 shares in the last quarter. Pacer Advisors Inc. bought a new stake in shares of Medidata Solutions during the third quarter worth $191,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Medidata Solutions by 5.3% in the second quarter. Tower Research Capital LLC TRC now owns 3,498 shares of the company’s stock worth $164,000 after buying an additional 177 shares in the last quarter. Hedge funds and other institutional investors own 99.63% of the company’s stock.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Medidata Clinical Cloud provides a platform of technology and data analytics solutions designed to manage activities across clinical development.

5 Day Chart for NASDAQ:MDSO

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.